Eli Lilly and Company (BIT:1LLY)

Market Cap	817.21B +39.6%
Revenue (ttm)	62.66B +47.4%
Net Income	21.92B +127.6%
EPS	24.42 +129.1%
Shares Out	n/a
PE Ratio	37.28
Forward PE	28.54
Dividend	2.57 (0.28%)
Ex-Dividend Date	Nov 13, 2025

Volume	242
Open	930.70
Previous Close	934.60
Day's Range	928.60 - 949.20
52-Week Range	535.20 - 972.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 30, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 50,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD